Giuseppe Seminara

Dr. Giuseppe Seminara


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
Stefano PalombaStefano Palomba
Stefano Palomba
GSGiuseppe Seminara
Giuseppe Seminara
FCFlavia Costanzi
Flavia Costanzi
DCDonatella Caserta
Donatella Caserta
Antonio AversaAntonio Aversa
Antonio Aversa
Background: Chemerin, an adipokine implicated in inflammatory, metabolic, and adipogenic processes, has been detected in high serum concentration in women with polycystic ovary syndrome (PCOS) and seems to play a role in PCOS pathogenesis. Moreover, at present, no comprehensive and critical document is available in the literature on this topic. The aim of the current study was to comprehensively review the latest available data to confirm the evidence about the association between chemerin and PCOS, highlighting its potential role as an upcoming biomarker and therapeutic target. Methods: A search in the literature of studies published between 2019 and 2024 was conducted using PubMed, Cochrane Library, and Web of Science, focusing on research related to chemerin, PCOS, and PCOS-related features, comorbidities, and complications. A qualitative structured synthesis of key findings was performed according to the specific thematic areas selected, including and discussing clinical data on women with PCOS and experimental studies in humans and animal models of PCOS. Results: Available data confirm increased serum levels of chemerin in women with PCOS compared with controls, independent of obesity and body mass index. Chemerin is associated with insulin resistance, hyperandrogenism, and ovarian dysfunction in PCOS individuals, inhibiting folliculogenesis and steroidogenesis. Experimental animal models underscore chemerin’s regulatory roles through its receptors within the hypothalamic–pituitary–ovarian axis and peripheral tissues. High systemic levels of chemerin in PCOS may also be related to the increased risk of pregnancy complications, especially gestational diabetes mellitus and preeclampsia. Conclusions: The current review study highlights the role of chemerin in PCOS pathophysiology, severity, and associated comorbidities and complications, assessing its value as a future biomarker and foreshadowing its potential as a therapeutic target.

Verified
Journal Article
Open access
PDF file
PCPaola Chiarello
Paola Chiarello
Gianmarco GualtieriGianmarco Gualtieri
Gianmarco Gualtieri
SBSabrina Bossio
Sabrina Bossio
GSGiuseppe Seminara
Giuseppe Seminara
MMMarianna Molinaro
Marianna Molinaro
Antonio AversaAntonio Aversa
Antonio Aversa
Congenital hypogonadotropic hypogonadism (CHH) is a rare and heterogeneous genetic disorder with variable penetrance caused by GnRH deficiency, leading to delayed puberty and infertility. In 50–60% of cases, CHH is associated with non-reproductive abnormalities, most commonly anosmia/hyposmia (Kallmann syndrome, KS). Over 60 genes have been implicated in CHH pathogenesis. We aimed to perform genetic screening in a cohort of 14 patients (10 males, 4 females; mean age 22 ± 7.72 years) with suspected or diagnosed HH/KS. Genetic analysis was conducted using next-generation sequencing (NGS) with a custom panel of 46 candidate genes. Variant interpretation followed ACMG standards and guidelines. Multiple tools were used to predict the structural effects of variants on tertiary protein structure, assessing their pathogenicity. Novel variants were functionally characterized by qRT-PCR on mRNA extracted from peripheral leukocytes. NGS identified nine rare variants and four novel variants in genes previously associated with normosmic isolated HH (nHH) and/or KS (FGFR1, PROK2, TAC3R, DCC, WDR11, IL17RD, DUSP6, KAL1, FGF8, IL17RD and DCC). The variant in TAC3R (p.Trp275Ter) was pathogenic; variants in ANOS1 (c.541+1G>A), IL17RD (c.1303_1304dup, p.Lys436ThrfsTer58), and TAC3R (p.Lys361Ter) were likely pathogenic. Nine variants were classified as variants of uncertain significance (VUS). Our study identified a possible genetic cause in 71% of the CHH/KS cohort, emphasizing the importance of genetic screening and functional characterization of genetic variants in patients with a phenotypically and genetically heterogeneous disorder like CHH.

24 January 2023 in Sexes
Verified
Journal Article
Open access
PDF file
SIStefano Iuliano
Stefano Iuliano
GSGiuseppe Seminara
Giuseppe Seminara
MZMaria Carmela Zagari
Maria Carmela Zagari
LLLuigi Di Luigi
Luigi Di Luigi
Antonio AversaAntonio Aversa
Antonio Aversa
The coronavirus disease 2019 (COVID-19) is an emerging pandemic caused by a novel coronavirus (SARS-CoV-2). Since December 2019 the new virus has spread all over the world and has become a major health problem also because of the public measures that could affect people’s sexual activity. We report a case of a 35-year-old married male admitted to the andrology outpatient clinic in July 2021 because of sudden onset erectile dysfunction (ED). The diagnostic workup showed no risk factor for ED, normal levels of testosterone, increased levels of endothelial dysfunction markers, such as CRP (C-Reactive Protein) and Endothelin-1, and reduced Vitamin D (VD) levels. Dynamic penile duplex ultrasound (D-PDU) revealed dysfunctional penile arterial flow. The five-item International Index of Erectile Function (IIEF-5) and the Short-Form Health Survey (SF-36) showed a reduction in all domain scores. The patient, initially unresponsive to the high dose oral phosphodiesterase 5 inhibitors (PDE-5is), was treated with vitamin-D and then submitted to LI-SWT (low intensity shockwave treatment), with a progressive clinical benefit at the 12-month follow-up. After 18 months, hormone levels persisted in normal ranges, with a consistent reduction in CRP and Endothelin-1. Additionally, IIEF-5, SF-36 and arterial flow significantly improved over the follow-up period. Thus far, the erectile function was restored and the patient is no more treated with PDE-5i.

16 October 2025 in Sexes
Verified
Journal Article
Open access
PDF file
GSGiuseppe Seminara
Giuseppe Seminara
MAMarco Alessi
Marco Alessi
MZMaria Carmela Zagari
Maria Carmela Zagari
FGFrancesca Greco
Francesca Greco
ARAntonino Raffa
Antonino Raffa
CMCristiano Monarca
Cristiano Monarca
Gender dysphoria stems from incongruence between gender identity and assigned sex, often causing significant distress related to breast anatomy in transmasculine individuals. Gender-affirming hormone therapy typically precedes mastectomy, which is a fundamental intervention in transgender healthcare. Surgical challenges arise in patients with large breasts on lean frames, requiring customized techniques to achieve a natural, proportional, androgynous chest. This case report describes a 23-year-old transmasculine patient with macromastia and a tall, lean build who underwent gender-affirming mastectomy with free nipple grafts and muscular sculpture aimed at an androgynous esthetic. Pre- and postoperative evaluations showed marked improvements in body image, physical strength performance, and emotional well-being. Psychological assessments revealed significant reductions in body uneasiness and gender dysphoria, while human figure drawings demonstrated increasing bodily integration and identity congruence. A general improvement in physical performance over time was reported, particularly in upper body strength, with minor fluctuations potentially related to the surgical intervention and recovery phase. The narrative literature review supports these outcomes, highlighting satisfaction rates above 90%, minimal regret, and consistent gains in psychosocial functioning and sexual and mental health, including reduced anxiety and depression. This evidence reinforces that gender-affirming mastectomy is medically necessary, particularly when tailored to individual anatomical and esthetic needs, affirming identity and alleviating distress.

16 July 2024 in Sexes
Verified
Journal Article
Open access
PDF file
PCPaola Chiarello
Paola Chiarello
GSGiuseppe Seminara
Giuseppe Seminara
SBSabrina Bossio
Sabrina Bossio
LSLuciana Sicilia
Luciana Sicilia
FGFrancesca Greco
Francesca Greco
Antonio AversaAntonio Aversa
Antonio Aversa
Gynecomastia in adolescence is a benign condition that mostly disappears spontaneously within approximately two years from onset. When it is associated with hypogonadism, it may suggest a disorder of sexual differentiation. We report the case of a young man (18 years old) with gynecomastia associated with azoospermia, small testes, hyperestrogenism and hypergonadotropic hypogonadism. A karyotype 46,XX was found, and searching for SRY (sex-determining region Y) by fluorescence in situ hybridization (FISH) highlighted the presence of the gene on the terminal region of the short arm, with breakpoints likely in Xp22.3 and Yp11.3. Implications of testosterone replacement therapy with respect to sex differentiation disorder and to physical performance are discussed.

24 January 2025 in Healthcare
Verified
Journal Article
Open access
PDF file
FGFrancesca Greco
Francesca Greco
LSLuciana Sicilia
Luciana Sicilia
GSGiuseppe Seminara
Giuseppe Seminara
SIStefano Iuliano
Stefano Iuliano
VTVera Tocci
Vera Tocci
Paolo SgròPaolo Sgrò
Paolo Sgrò
Background/Objectives: Thyroid hormones (THs) are correlated with body composition regardless of the presence of thyroid dysfunctions, whereas little is known regarding THs’ influence on muscular fitness components. This cross-sectional study investigated whether THs may affect muscular parameters in adults who are overweight and affected obesity. Methods: One hundred and five volunteers (65 females and 40 males, BMI: 33.5 (8.0) kg/m2) in an euthyroid state were enrolled. Body composition was evaluated using bioelectrical impedance analysis. Muscular parameters of interest were grip strength—evaluated using the handgrip test (HG) and muscular performance –evaluated using the 10-repetition chair-stand test (CST). Free-triiodothyronine (FT3), free-thyroxine (FT4) and their ratio (FT3/FT4) were evaluated to assess thyroid function. Results: In the female group, the Pearson linear regression analysis revealed a positive correlation between FT3 and HG (R = 0.261, p = 0.036) and a negative correlation between FT3/FT4 and CST (R= −0.266, p= 0.032). In the male group, a positive correlation between FT3 and skeletal muscle mass was found (R = 0.354, p = 0.025). No correlations were found between THs of interest and adiposity indexes (BMI, fat mass) in either group (p > 0.05). Conclusion: FT3 and FT3/FT4 ratio levels in euthyroidism may influence muscular parameters differently in females and males affected by an excess of fat mass. More research is needed to understand the mechanisms behind this correlation and whether THs could be a potential biomarker for muscle-related parameters.